Literature DB >> 8683144

Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells.

J P Drenth1, J W van der Meer, I Kushner.   

Abstract

The hyper-IgD and periodic fever syndrome (HIDS) and familial Mediterranean fever (FMF) are both characterized by attacks of periodic fever accompanied by acute phase responses that are substantially higher in HIDS than in FMF. To determine whether this difference could be due to differences in production of acute phase protein-inducing mediators, we studied PBMC from HIDS and FMF patients in the inactive phase of disease. Unstimulated PBMC from patients with inactive HIDS released significantly more IL-1 beta, IL-6, and TNF-alpha than did PBMC from patients with FMF, but unstimulated PBMC from the latter group released significantly more IL-1 beta and IL-6 compared with controls. Conditioned medium (CM) derived from PBMC of patients with inactive HIDS induced significantly greater CRP production and significantly higher mRNAs for CRP and SAA in Hep3B cells than did CM derived from the PBMC of patients with inactive FMF. Stimulation of PBMC with LPS led to further increases in cytokine production and in acute phase protein-inducing ability in both patient groups and in controls. These findings suggest that the greater acute phase response seen in HIDS compared with FMF reflects greater production of acute phase protein-inducing cytokines in the former patients and indicates that PBMC from inactive HIDS patients are already activated in vivo. Finally, the finding of both quantitative and qualitative differences in cytokine production by unstimulated PBMC from HIDS and FMF patients supports the likelihood of different pathogeneses of these diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  A patient with hyper-IgD syndrome responding to anti-TNF treatment.

Authors:  Erkan Demirkaya; M Kazim Caglar; Hans R Waterham; Rezan Topaloglu; Seza Ozen
Journal:  Clin Rheumatol       Date:  2006-12-15       Impact factor: 2.980

2.  Anti-interleukin 6 receptor therapy for hyper-IgD syndrome.

Authors:  Anne Musters; Paul Peter Tak; Dominique L P Baeten; Sander W Tas
Journal:  BMJ Case Rep       Date:  2015-10-29

3.  The sphingomyelin-ceramide pathway participates in cytokine regulation of C-reactive protein and serum amyloid A, but not alpha-fibrinogen.

Authors:  G Lozanski; F Berthier; I Kushner
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

4.  Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease.

Authors:  Frank L van de Veerdonk; Sanne P Smeekens; Leo A B Joosten; Bart Jan Kullberg; Charles A Dinarello; Jos W M van der Meer; Mihai G Netea
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

5.  Treatment of Inflammatory Diseases with IL-1 Blockade.

Authors:  Charles A Dinarello
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-03-07

6.  Profile of blood cells and inflammatory mediators in periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome.

Authors:  Kelly L Brown; Per Wekell; Veronica Osla; Martina Sundqvist; Karin Sävman; Anders Fasth; Anna Karlsson; Stefan Berg
Journal:  BMC Pediatr       Date:  2010-09-06       Impact factor: 2.125

Review 7.  Inborn errors of metabolism underlying primary immunodeficiencies.

Authors:  Nima Parvaneh; Pierre Quartier; Parastoo Rostami; Jean-Laurent Casanova; Pascale de Lonlay
Journal:  J Clin Immunol       Date:  2014-08-01       Impact factor: 8.317

8.  Co-existence of Hashimoto's thyroiditis with familial Mediterranean fever: is there a pathophysiological association between the two diseases?

Authors:  E Gulcan; A Gulcan; M Koplay; A Alcelik; U Korkmaz
Journal:  Clin Exp Immunol       Date:  2009-02-19       Impact factor: 4.330

Review 9.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.

Authors:  Charles A Dinarello; Anna Simon; Jos W M van der Meer
Journal:  Nat Rev Drug Discov       Date:  2012-08       Impact factor: 84.694

10.  30 years hids-Travels between bedside and bench.

Authors:  Jos W M van der Meer
Journal:  Temperature (Austin)       Date:  2015-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.